Cerus Corporation

CERS Healthcare Medical Devices

In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.

2.20 0.06 −2.65%
Market cap
$455.5M
P/E
0.0×
Fwd P/E
−81.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a

Insider Decisions trades per month

Total sells 3.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — — 9 — 2 5 1 1 — —
Insider Ownership 4.93%

Capital & Financial Ratios $m

Market Cap 455.45
Revenue 248.01
Net Income (6.83)
Free Cash Flow (1.83)
Net Debt 8.65
Current Ratio 1.83 (at or above 1.5: strong)
Debt/Equity 0.92
P/E ratio 0.00
Fwd P/E (81.30) (negative: loss-making)
P/S ratio 1.78
P/B ratio 6.24 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 43.75% (at or above 15%: strong)
Next Y EPS Growth 72.22% (at or above 15%: strong)
Next Y revenue growth 6.50%
Next 5Y EPS Growth 54.33% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/S against its own 10 years 18.91%
10-year low 10-year high
P/B against its own 10 years 20.68%
10-year low 10-year high
EV/Sales against its own 10 years 19.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 66 80 83 56
Receivables 36 30 30 31
Inventory 40 38 56 66
Other — — — —
144 152 174 157
2023 2024 2025 Q'26
Payables 24 22 28 34
ST’ Debt 20 19 43 30
Other — — — —
68 64 101 86

Compound Annual Growth %

10y 5y 3y
Sales 21.19% 15.40% 7.48%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (3.71%) (8.95%) (1.78%)

Revenue $m

Mar Jun Sep Dec Year
’26 60 63 — — —
’25 49 60 60 65 234
’24 43 51 51 57 201
’23 38 48 47 53 187
’22 43 48 46 51 188
’21 30 38 42 50 160
’20 25 27 29 34 114
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (1) (2) 2 6 5
’24 2 0 4 5 11
’23 (8) (9) (10) (15) (43)
’22 (21) 0 (2) (2) (26)
’21 (17) (9) (7) (1) (34)
’20 (20) (8) (5) (9) (42)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) — — —
’25 (1) (3) 0 5 1
’24 1 0 3 4 9
’23 (10) (9) (13) (15) (48)
’22 (22) 0 (3) 37 12
’21 (18) (9) (7) (2) (35)
’20 (20) (8) (5) (9) (43)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.01) (0.01) — — —
’25 (0.04) (0.03) 0.00 (0.01) (0.08)
’24 (0.05) (0.03) (0.02) (0.01) (0.11)
’23 (0.09) (0.07) (0.04) (0.01) (0.21)
’22 (0.07) (0.05) (0.05) (0.08) (0.24)
’21 (0.10) (0.09) (0.07) (0.05) (0.32)
’20 (0.10) (0.09) (0.08) (0.09) (0.37)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.17 1.93 3.38 3.70 2.71 4.67 3.25 1.21 1.38 1.12

Analyst estimates 2026–2028

Powerpack
High 7.64 4.70 8.05 6.88 8.87 8.41 7.01 4.05 2.59 2.26
People
People Employees 204 215 240 254 270 294 309 288 281 275
Revenue/emp, $m 0.19 0.24 0.32 0.37 0.42 0.54 0.61 0.65 0.72 0.85
Income, $m
Income, $m Revenue 39 51 76 94 114 160 188 187 201 234
Gross margin, % 48.33 56.10 58.40 64.36 63.98 60.21 60.20 62.54 59.89 59.86
EBT (63) (57) (57) (71) (60) (54) (42) (37) (21) (15)
EBT margin, % (159.72) (110.47) (75.39) (75.69) (52.14) (33.89) (22.48) (19.98) (10.31) (6.54)
Net income (63) (61) (58) (71) (60) (54) (43) (38) (21) (16)
Depreciation 2 2 1 2 3 3 3 3 2 1
Per share, $
Per share, $ Revenue 0.39 0.47 0.58 0.67 0.70 0.93 1.07 1.04 1.09 1.23
Earnings (0.62) (0.56) (0.44) (0.51) (0.37) (0.32) (0.24) (0.21) (0.11) (0.08)
Cash flow (0.53) (0.48) (0.24) (0.47) (0.25) (0.20) (0.15) (0.24) 0.06 0.03
Capex (0.01) 0.00 (0.01) (0.06) (0.01) (0.01) 0.22 (0.03) (0.02) (0.02)
Free cash flow (0.53) (0.49) (0.25) (0.53) (0.26) (0.20) 0.07 (0.26) 0.05 0.01
Book value 0.57 0.36 0.64 0.41 0.63 0.50 0.39 0.30 0.31 0.34
Shares, m 102 108 132 140 164 171 177 180 185 191
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 11.23 7.51 8.78 6.29 9.93 7.31 3.51 2.08 1.41 1.68
P/B 7.63 9.89 7.90 10.34 10.93 13.62 9.63 7.29 5.00 6.04
EV/Sales 9.90 7.01 7.62 5.85 9.18 6.94 3.33 2.16 1.43 1.68
EV/FCF (7.18) (6.84) (17.90) (7.37) (24.16) (31.77) 50.28 (8.44) 33.79 355.26
Cash, $m
Cash, $m Operating cash flow (54) (52) (31) (65) (42) (34) (26) (43) 11 5
Capex (1) 0 (1) (9) (2) (1) 38 (5) (3) (4)
Free cash flow (54) (53) (32) (74) (43) (35) 12 (48) 9 1
Balance, $m
Balance, $m Working capital 67 67 94 78 123 109 53 77 88 74
Total debt 19 30 30 44 48 69 70 80 84 84
Net debt (52) (31) (88) (41) (85) (60) (32) 14 4 1
Shareholders’ equity 58 39 85 57 104 86 69 53 57 65
Returns, %
Returns, % ROA (51.80) (60.07) (43.99) (43.31) (30.94) (23.70) (18.78) (18.03) (10.49) (7.39)
ROIC (693.97) (447.11) 0.00 (262.55) (199.05) (119.11) (58.82) (27.87) (14.67) (8.22)
ROE (82.47) (125.27) (93.25) (100.65) (74.42) (57.41) (55.49) (61.45) (37.92) (25.65)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Cerus Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TCMD Tactile Systems Technology, Inc. $527.6M 20.5× 22.7× +8.61% (above 0%: growing) +142.86% (above 0%: growing) −86.53% (below 0%: shrinking) 76.25% 7.97% Compare
SSII SS Innovations International, Inc. $517.2M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
DCTH Delcath Systems, Inc. $513.9M 1,408× — (loss-making) +20.60% (above 0%: growing) −12.50% (below 0%: shrinking) −24.45% (below 0%: shrinking) 89.75% 8.22% Compare
MASS 908 Devices Inc. $491.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
SGHT Sight Sciences, Inc. $484.8M — (loss-making) — (loss-making) +19.55% (above 0%: growing) n/m +26.71% (above 0%: growing) 91.39% (16.62%) Compare
BWAY Brainsway Ltd. Sponsored ADR $475.8M 24.8× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
CERS Cerus Corporation $455.5M — (loss-making) — (loss-making) +5.28% (above 0%: growing) n/m −20.90% (below 0%: shrinking) 55.91% (2.94%)
NPCE NeuroPace, Inc. $438.7M — (loss-making) — (loss-making) +17.05% (above 0%: growing) n/m −78.70% (below 0%: shrinking) 82.83% (22.53%) Compare
SENS Senseonics Holdings, Inc. $435.2M — (loss-making) — (loss-making) +117.82% (above 0%: growing) n/m −223.24% (below 0%: shrinking) 59.10% (248.48%) Compare
Median of peers $488.1M 24.8× — +21.96% +40.00% −38.07% 75.44% (16.45%)

All 149 Medical Devices stocks →

Cerus Corporation (CERS) key facts

  • Cerus Corporation (CERS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CERS traded at $2.20, a market capitalization of $455.5 million.
  • Return on equity was −25.7% and debt-to-equity 0.92.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Cerus Corporation (CERS) Latest News

30 Apr

Impact 4 · transcript
Impact 4 ·
stockrow.com/CERS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com